Literature DB >> 10630693

Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial.

F Locatelli1, C Pozzi, L Del Vecchio, S Andrulli, A Pani, G Fogazzi, P Altieri, C Ponticelli.   

Abstract

Corticosteroids have had variable success in IgA nephropathy (IgAN). Our previous trial with a six-month course of steroids in IgAN patients showed they were effective in reducing the risk of renal function deterioration and proteinuria, but this effect seemed to decrease in the long term. This new randomised trial was designed to prospectively evaluate whether adding low-dose azathioprine to steroids improves long-term renal survival in adult biopsy-proven IgAN patients with proteinuria > or = 1 g/24 h and plasma creatinine < or = 2.0 mg/dl. The patients will be treated with steroids (methylprednisolone 1 g i.v. for three consecutive days at months 1, 3 and 5, plus oral prednisone 0.5 mg/kg every other day for six months) plus azathioprine 1.5 mg/kg/day for six months or steroids alone with the same schedule. Altogether a minimum of 346 patients should be enrolled within a four-year recruitment period. The planned duration of follow-up is five years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630693

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  2 in total

1.  Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.

Authors:  Claudio Pozzi; Simeone Andrulli; Antonello Pani; Patrizia Scaini; Lucia Del Vecchio; Giambattista Fogazzi; Bruno Vogt; Vincenzo De Cristofaro; Landino Allegri; Lino Cirami; Aldo Deni Procaccini; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2010-07-15       Impact factor: 10.121

2.  A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616].

Authors:  Ronald J Hogg; Robert J Wyatt
Journal:  BMC Nephrol       Date:  2004-03-25       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.